PROSTATE CANCER AND PROSTATIC DISEASES
Scope & Guideline
Elevating standards in prostate disease management.
Introduction
Aims and Scopes
- Clinical Management and Treatment Strategies:
The journal emphasizes research on various treatment modalities for prostate cancer, including surgical techniques, radiation therapy, and hormonal treatments, aimed at improving clinical outcomes and patient quality of life. - Diagnostic Innovations:
There is a strong focus on the development and validation of diagnostic tools, such as imaging techniques (e.g., MRI, PSMA PET) and biomarkers, which are crucial for early detection and accurate staging of prostate cancer. - Patient-Centered Research:
The journal highlights studies that address patient experiences, decision-making processes, and the psychosocial aspects of prostate cancer treatment, emphasizing the importance of patient-reported outcomes. - Epidemiology and Health Disparities:
Research addressing the epidemiology of prostate cancer, including risk factors, health disparities among different populations, and the impact of socioeconomic factors on treatment access and outcomes, is a key area of interest. - Translational Research and Precision Medicine:
The journal supports studies that bridge laboratory research and clinical application, focusing on personalized medicine approaches, genetic profiling, and the role of molecular markers in treatment response. - Multidisciplinary Approaches:
The journal encourages collaborative research that integrates insights from urology, oncology, radiology, pathology, and other disciplines to advance comprehensive care strategies for prostate cancer patients.
Trending and Emerging
- Advanced Imaging Techniques:
There is a growing emphasis on the use of advanced imaging modalities, such as multiparametric MRI and PSMA PET scans, for the detection, staging, and monitoring of prostate cancer, reflecting technological advancements in diagnostics. - Biomarker Development and Precision Oncology:
Research focused on the identification and validation of biomarkers for prostate cancer prognosis and treatment response is on the rise, highlighting the trend towards precision medicine and individualized treatment strategies. - Health Disparities and Societal Impact:
Emerging studies addressing health disparities in prostate cancer incidence, treatment access, and outcomes among different racial and ethnic groups indicate a growing awareness of the social determinants of health. - Integration of Artificial Intelligence in Diagnostics:
The application of artificial intelligence and machine learning in improving diagnostic accuracy and treatment planning for prostate cancer is a rapidly emerging area, reflecting the increasing intersection of technology and healthcare. - Holistic and Multidisciplinary Care Approaches:
There is a trend towards research that emphasizes holistic care, integrating psychological support, lifestyle interventions, and patient education into the management of prostate cancer, indicating a shift to more comprehensive patient care models.
Declining or Waning
- Traditional Surgical Techniques:
There has been a noticeable reduction in publications focused solely on traditional surgical techniques for prostate cancer, as newer minimally invasive and robotic-assisted approaches gain traction and research emphasis. - Basic Science and Laboratory Studies:
Research articles centered on basic science and laboratory studies without direct clinical application have seen decreased representation, possibly due to a shift towards translational research that directly impacts patient care. - General Population Studies:
Publications investigating general population trends in prostate cancer incidence and treatment have declined, suggesting a shift towards more targeted studies that focus on specific populations or high-risk groups. - Historical Treatment Approaches:
As new therapies and methodologies emerge, there is less emphasis on historical treatment approaches that have been largely supplanted by more effective options, leading to fewer studies in this area. - Non-Oncological Prostate Conditions:
Research on benign prostatic hyperplasia and other non-cancerous prostate conditions appears to be waning, as the journal increasingly prioritizes studies that focus on prostate cancer and oncological outcomes.
Similar Journals
Breast Journal
Empowering clinicians with cutting-edge insights.The Breast Journal, published by Wiley-Hindawi, is a distinguished Open Access journal dedicated to the fields of internal medicine, oncology, and surgery with a particular focus on breast health and disease. Since its inception in 1995, the journal has become an essential resource for researchers and clinicians, facilitating the dissemination of high-quality research and innovative clinical practices. With an impact factor reflecting robust scholarly influence and a ranking in the Q3 quartile for both internal medicine and oncology, as well as Q2 in surgery, it showcases significant contributions that advance knowledge and improve patient outcomes. Offering unparalleled access to its articles, The Breast Journal aims to support a global audience in exploring the multifaceted challenges and breakthroughs in breast-related health, making it a vital platform for shared learning and scientific discourse.
LANCET ONCOLOGY
Discovering innovative solutions for complex oncology challenges.The Lancet Oncology is a premier peer-reviewed journal published by Elsevier Science Inc., recognized as a leading authority in the field of oncology. With an ISSN of 1470-2045 and E-ISSN 1474-5488, this esteemed journal boasts an impressive 2023 impact factor placing it in the Q1 category of oncology—reflecting its role as a critical resource for cutting-edge research. The journal publishes high-quality articles covering novel scientific discoveries, clinical advancements, and public health issues related to cancer treatment and prevention. It is ranked #5 out of 404 in the Scopus Medicine _ Oncology category, demonstrating its influence and relevance in the field, with an outstanding rank in the 98th percentile. Operating from its base in the United Kingdom, The Lancet Oncology spans a comprehensive timeframe from 2000 to 2024, making it a vital repository of oncology literature. Although it does not primarily operate on an open-access model, its significant subscription base ensures that a wealth of knowledge is accessible to researchers, professionals, and students alike, fostering a profound understanding and advancement in oncology.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
Driving clinical excellence through rigorous investigation.Urologic Oncology - Seminars and Original Investigations is a premier journal published by Elsevier Science Inc, dedicated to advancing the field of urologic oncology through high-quality, peer-reviewed research and insightful scholarly discussions. With an ISSN of 1078-1439 and an E-ISSN of 1873-2496, this journal has established itself as a vital resource for professionals, researchers, and students alike since its inception in 1995. Currently holding a Q2 ranking in Oncology and a prestigious Q1 in Urology for 2023, it ranks 28th out of 120 in Urology and 177th out of 404 in Oncology within Scopus, underscoring its relevance and impact in these critical fields. While the journal operates under a subscription model, it continues to deliver compelling and transformative research aimed at enhancing patient outcomes in urologic oncology. With a focus on innovative therapies, diagnostic advancements, and clinical trials, the journal contributes significantly to ongoing dialogue and development in urologic health care.
EUROPEAN UROLOGY
Elevating clinical practice with groundbreaking findings.EUROPEAN UROLOGY is a prestigious journal in the field of urology, published by Elsevier, and residing in the vibrant academic landscape of the Netherlands. Since its inception in 1975, the journal has made significant contributions to urological research, earning a top rank of #1 out of 120 in the Scopus category of Medicine - Urology, placing it within the esteemed 99th percentile of its field. With a commitment to disseminating cutting-edge research, clinical findings, and innovative practices, EUROPEAN UROLOGY has established itself as a pivotal resource for urologists and researchers alike. Although it does not offer open access options, it provides an indispensable platform for scholarly communication that drives advancements in patient care and medical knowledge. As the journal embarks on converged years leading up to 2024, it continues to strive for excellence in urology, welcoming contributions that reflect the latest scientific advancements and clinical applications.
Tumori Journal
Connecting Professionals in the Pursuit of Cancer Solutions.Tumori Journal is a distinguished publication in the field of oncology, dedicated to advancing the understanding and treatment of cancer since its inception in 1946. Published by SAGE Publications Ltd, this Italian journal serves as a pivotal platform for researchers, clinicians, and academicians to disseminate cutting-edge findings in cancer research and related areas of medicine. With an impressive record of contributions spanning multiple decades, Tumori Journal aims to foster collaboration and dialogue among professionals in the oncology community. Although classified in the Q4 category for Cancer Research and the Q3 category for both Medicine (miscellaneous) and Oncology as of 2023, the journal continues to draw interest with its rigorous peer-review process and commitment to quality. Researchers are encouraged to explore innovative methodologies and share impactful clinical insights through the journal, which also ranks within the top tiers of Scopus metrics for oncology and cancer research domains. With a growing emphasis on accessible research, Tumori Journal remains an essential resource in the continuous fight against cancer.
African Journal of Urology
Exploring Innovations in African UrologyAfrican Journal of Urology (ISSN: 1110-5704, E-ISSN: 1961-9987) is a leading scholarly publication in the field of urology, published by SPRINGER from the United Kingdom. Since adopting an open access model in 2012, this journal has aimed to increase the visibility and dissemination of vital research findings across the African continent and beyond. With a current impact factor and significant standing, as denoted by its Q3 ranking in Urology for 2023, it serves as an essential platform for clinicians, researchers, and students alike. The journal's scope encapsulates all aspects of urology, fostering advancements in both clinical practices and innovative research while specifically addressing healthcare challenges relevant to African populations. As part of its commitment to accessibility and academic excellence, the journal offers full open access to its content, allowing for a broad readership and engagement with cutting-edge studies. Engage with the African Journal of Urology to contribute to and stay informed about vital developments in urological science.
Urology Research and Practice
Fostering global dialogue in urology scholarship.Urology Research and Practice, published by AVES in Turkey, is an essential open-access journal dedicated to advancing the field of urology. With its inaugural issues released in 2023, the journal aims to disseminate cutting-edge research, innovative practices, and insightful clinical studies pertinent to urology, thereby fostering knowledge and collaboration among researchers, healthcare professionals, and students alike. Currently indexed in Scopus, it ranks Q3 in the urology category, reflecting its growing impact evidenced by a 47th percentile ranking in the Medicine Urology field. The journal not only serves as a platform for exceptional scholarly work but also emphasizes accessibility and inclusivity in scientific communication, allowing for a broader dissemination of urological knowledge globally. Explore groundbreaking research and contribute to the evolving landscape of urology through Urology Research and Practice.
BREAST
Exploring breakthroughs in breast disease management.BREAST is a leading peer-reviewed journal dedicated to advancing knowledge and practice in the fields of cancer research, oncology, and surgery, published by Churchill Livingstone. With an impressive impact factor and a prestigious Q1 ranking in multiple categories including Cancer Research, Medicine, and Surgery, the journal consistently delivers high-quality content that informs and inspires researchers, clinicians, and educators. Since its transition to Open Access in 2020, BREAST has significantly expanded its reach, providing immediate and unrestricted access to pivotal studies and findings in breast health and disease management. With a history dating back to 1992 and converging to 2024, the journal serves as an essential resource for the latest developments and innovative approaches in the clinical and biomedical aspects of breast care. Scholars and professionals alike can explore a wealth of research aimed at improving patient outcomes and fostering scientific dialogue in this vital area of healthcare.
PROSTATE
Innovating treatment through rigorous peer-reviewed studies.PROSTATE is a premier, peer-reviewed journal published by Wiley, focusing on the critical fields of urology and oncology. With an established history since 1980 and a projected convergence through 2024, this influential journal serves as a vital resource for researchers, clinicians, and students alike. It holds a prestigious position in the academic landscape, classified in the Q1 category for Urology and Q2 in Oncology as of 2023, demonstrating its significant contribution to these disciplines. With a Scopus rank of #23 in Urology and #169 in Oncology, PROSTATE is pivotal for advancing knowledge and fostering innovation in prostate research, treatment, and overall male health. The journal aims to publish high-quality original articles, reviews, and clinical studies that address the complexities of prostate-related conditions, ultimately seeking to improve patient outcomes and propagate best practices in the medical community.
Prostate Cancer
Fostering collaboration in the fight against prostate cancer.Prostate Cancer is a leading peer-reviewed Open Access journal published by HINDAWI LTD, dedicated to advancing the field of urology and oncology through high-quality research and innovative studies. Established in 2011, this journal serves as a vital platform for disseminating findings related to prostate cancer diagnostics, treatment strategies, and patient care, striving to collaborate and connect researchers from around the globe. With an impact factor reflective of its critical input in the scientific community, the journal showcases compelling manuscripts, reviews, and case reports that are accessible to a wide audience given its open access policy. Located in London, England, Prostate Cancer has made significant strides in its category quartiles, achieving Q4 in Cancer Research and Q3 in both Oncology and Urology as of 2023, reflecting its growing relevance and readership. With Scopus rankings indicating its position within the broader medical fields, the journal is a valuable resource for researchers, professionals, and students alike, contributing to the collective effort to improve outcomes in prostate cancer research and treatment.